BLB(SZ:002286)2025-01-15 09:04Financial Performance - The company expects net profit attributable to shareholders to be between 10,793.80 million and 12,412.87 million yuan, representing a year-on-year growth of 100%-130%[2] - The net profit after deducting non-recurring gains and losses is projected to be between 12,293.80 million and 13,912.87 million yuan, indicating a year-on-year increase of 251.82%-298.16%[2] - The basic earnings per share is estimated to be between 0.2919 yuan and 0.3357 yuan, compared to 0.15 yuan in the same period last year[2] Cost Management - The decline in procurement costs for key raw materials such as corn and corn starch has effectively reduced cost pressures[5] - The company has achieved significant improvements in gross profit margin through enhanced supply chain management and process optimization[4] Product and Market Strategy - Sales of high-value-added products, including differentiated glucose syrup and high-end prebiotics, have significantly increased, contributing to higher profits[5] - The company has improved marketing efficiency by adjusting strategies and focusing on high-margin products, leading to better overall profitability[6] - Continuous investment in R&D and technology upgrades has enhanced product competitiveness, particularly in prebiotics and dietary fibers[6] - The company is actively expanding into emerging high-value areas such as sugar-free dietary fibers and HMO, strengthening its domestic market while accelerating international expansion[7] Cautionary Note - The financial data presented is preliminary and will be detailed in the 2024 annual report, urging investors to exercise caution[8]